On Tuesday, The House of Representatives discussed the Trump proposal for the institution of step-therapy process into medicare plans. Read more
FOR IMMEDIATE RELEASE
April 26, 2019
Barry D. Brooks, M.D., Joins NCODA Executive Council
Cazenovia, NY – The National Community Oncology Dispensing Association, Inc. (NCODA)is pleased to announce the addition of Barry D. Brooks, M.D. to their Executive Council. Dr. Brooks joined the Council in April.
Barry D. Brooks, M.D., is a hematologist and medical oncologist with Texas Oncology and for 17 years has worked as physician-lead on the Drug Contracting committee of US Oncology. He was Chair of P&T from 2011 to 2018 and now serves as Medical Director of Oral Oncolytics for USON. He is the author of many publications and abstracts in the field of oncology. ”Being part of NCODA is a great honor. I believe NCODA will do for oncology dispensing what COA has done for community oncology by improving access to oral oncology drugs for America’s cancer patients and giving patients a voice in Washington. ”, said Dr. Brooks.
“Dr. Brooks, in addition to being an outstanding medical oncologist, is a dynamic individual who will bring a great deal of insight from a physician’s perspective to our NCODA initiatives” said Jim Schwartz, NCODA President and Executive Council Chair.
For more information about NCODA’s Executive Council and general updates visit ncoda.org or read the official release here.
In what initially appeared to be a move that directly opposed the efforts of state legislation recently passed in the Virginias, CMS is allowing the use of copay accumulators but only in situations in which a generic drug is available. Luckily for our cancer patients, this should largely not affect them (as copay cards are generally only available on brands without a generic). Alas, more legislation will be needed to protect patients in all 50 states and around the world.
A US Senate Finance Committee hearing on drug pricing focused on addressing the role of pharmacy benefit managers (PBMs) in determining cost to patients. NCODA notes that the Executives from these companies dodged key questions around their policies’ impact on cancer patients. We will continue to support state legislation that increases transparency with the PBMs and passes savings to patients. read more